TO THE EDITOR
Recently, we confirmed that partial duplication of the long arm of chromosome 21, dup(21), including the 21q22 chromosomal region and amplification of AML1, is a recurring chromosomal abnormality in acute lymphoblastic leukemia (ALL). Multiple copies of the AML1 gene were identified in 20 patients during routine screening by interphase fluorescence in situ hybridization (FISH) for the presence of the TEL/AML1 fusion. 1 Together with the sporadic cases reported in the literature, our study raised the total number of published cases to 30. We now report a further eight patients with the same abnormality and comment on the survival of the 28 patients from our original series.
The eight new cases were from the same ALL childhood treatment trials as previously reported, 1 and were included in this study with parental consent. They were identified using similar procedures. 1 Additional copies of signals for the AML1 gene were observed in six of the new cases by routine interphase FISH screening. The other two cases were identified during a retrospective cytogenetic review of G-banded slides from cases that showed monosomy 21 in association with unidentified marker chromosomes. The markers in all eight cases had the characteristic morphology of a dup(21) chromosome (Table 1) , as previously described. 1 Although observed by others (Najfeld V. Blood 1998; 92: 396a), 2, 3 we are still unable to confirm AML1 amplification in cases with a normal karyotype. In all the eight cases, metaphase FISH with the TEL/AML1 probe confirmed that the multiple copies of AML1 were confined to duplicated chromosomes 21. The number of AML1 signals per cell for each case is shown in Table 1 . The involvement of the AML1 gene within the amplified regions was confirmed using two AML1 exon-specific probes in cases with available material (patients 3767, 4780, 5655, 5674 and 5898), as previously described. 1 The karyotypes defined by conventional cytogenetics, or in two cases by multiplex-FISH (M-FISH) (4780, 5898), were similar to those seen in the previously reported cases. They were near-diploid with 45-47 chromosomes, the dup(21) replacing one normal copy of chromosome 21, this being the sole abnormality in two patients.
The patients had a median age of 8 years (range 5-11 years). The seven cases with known immunophenotypes were all common/pre-B ALL. All the original 20 patients had a WBC o20 Â 10 9 /l. However, in three of the new patients, the WBC was 450 Â 10 9 /l at presentation. The most recent follow-up on all 28 patients showed that 12 of them had relapsed, either as an isolated bone marrow (n ¼ 9) or an isolated central nervous system (n ¼ 3) relapse ( Figure 1 ).
Relapse occurred between 4 and 57 months. Eight patients relapsed while still on treatment and nine of the 12 patients have subsequently died, six of them having only a short second remission. One patient (4414) died in remission 8 months following diagnosis. Among the 16 patients who have not so far suffered an adverse event, nine have o2 years follow-up, and only two are alive and well more than 3 years after diagnosis ( Figure 1 ). Overall, these data suggest that the amplification of AML1 is associated with a poor outcome. There was no association between the form of the dup(21) and relapse, since all the five morphological types were observed in the relapse patients. Fixed cell suspensions were available from two relapse bone marrow samples (patients 2423 and 4134). Although there was evidence of minor karyotypic evolution between the diagnostic and relapse samples in both patients, interphase FISH and cytogenetic analysis revealed that the level of amplification, as established by AML1 signal copy number, and the G-banded appearance of the dup(21) remained unchanged. This indicates that, although the dup(21) chromosomes are clearly heterogeneous in form, they appear to be stable throughout cell division.
Identification of further eight patients with amplification of AML1 on a duplicated chromosome 21 reinforces this as a cytogenetic subgroup in ALL, occurring at an estimated incidence of 1.5% in childhood ALL. The inclusion of two other recently described cases 4, 5 increases the total number reported to 40. A longer follow-up of our 28 cases suggests that the presence of a duplicated chromosome 21, together with multiple copies of the AML1 gene, is indicative of a poor prognosis in ALL. TO THE EDITOR Down's syndrome (DS) children have the 10-to 20-fold increased risk of developing acute leukemia compared with non-DS children. Acute myeloid leukemia (AML) in DS children shows unique characteristics as to be a predominance of the megakaryoblastic leukemia (AMkL) and a preceding history of the transient myeloproliferative disorder (TMD), whose blasts are morphologically and phenotypically indistinguishable from those of AMkL. TMD is developed in about 10% of DS infants and resolves spontaneously in most cases. However, 20% of TMD cases develop AMkL within 3 years, suggesting that additional genetic alterations might occur during the progression from TMD to AMkL. Recently, somatic mutations of the GATA1 gene were reportedly associated with AMkL of DS children. 1 In addition, it was reported that GATA1 mutations were present in the TMD blasts, and that the identical GATA1 mutation was found in sequential samples collected from a patient during TMD and subsequent AMkL. [2] [3] [4] [5] These results suggested that GATA1 mutations are an early event in DS leukemogenesis and contribute 
